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Abstract 
Burkitt Lymphoma (BL) is a highly aggressive B cell non Hodgkin lymphoma. It’s considered 
the fastest growing human tumor and it is commonly associated with EBV infection. It was 
the first type of cancer shown to have a chromosomal translocation that activates c-Myc to 
become an oncogene. This genetic rearrangement places myc that usually is on chromosome 
8 under the immunoglobulin gene regulatory element on chromosome 14 resulting in tumor 
promoting effect. BL is a highly malignant B-cell neoplasm that occurs endemically in 
equatorial Africa and sporadically throughout the world. The endemic BL (eBL) is the 
pediatric form positive for EBV in most cases. The variant of BL affecting the rest of the world 
is the sporadic BL (sBL) which is found in older patients and it is considered EBV negative 
because only a minority is EBV infected. The World Health Organization recognizes also a 
third form, HIV-BL which develops in HIV positive patients.  
Although, until now  the translocation 8-14 and its variants are considered the major 
mechanism for the pathogenesis of BL, other molecular mechanism such as microRNA 
expression profile have been used to characterize and classify different types of BL from 
other lymphoma malignancies. However, the differential expression of microRNAs between 
BL patients and healthy control has not been studied before. For this reason our goal is to 
investigate the functional role of microRNAs that are disregulated in BL patients compared 
to healthy (cancer free) individuals. MicroRNAs are noncoding RNA, 18-24 nucleotides long. 
They are transcribed in the nucleus as long primary transcripts, and then cut by Drosha and 
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DGCR8 into 70 nucleotides long precursors (pre-miRNA). This Pre-Mir is exported to the 
cytoplasm by Exportin-5 and then cleaved into a mature dsRNA by Dicer. Only one strand of 
the duplex miRNA-miRNA* binds the target mRNA to modulate the gene expression through 
two principle mechanisms which are the degradation of mRNA or the inhibition of the 
protein translation. 
 To gain further insight into the molecular pathology of BL, we performed miRNA expression 
profile using a set of 5 sporadic, and 2 endemic BL patients, compared to B cells from reactive 
lymph nodes of 9 healthy patients and 11 patients affected by mononucleosis. MiRNAs 
expression signature shows, among the group of downregulated miRNAs, miR-221 that 
usually is upregulated in solid tumors. This is the first microRNA profiling that has been done 
in BL using as negative control lymph nodes taken from reactive patients or patients affected 
by the EBV virus, whereas the literature shows microRNA profiles in BL using as negative 
control T cells or different type of B cell lymphomas like for example DLBL (diffuse large B 
cell lymphoma). To confirm the remarkable down-regulation of miR-221 a nanoString 
analysis in 2 different cohorts of BL cell lines was also performed. We observed a common 
trend of altered expression of microRNAs, highlighting once again the down-regulation of 
miR-221/222, suggesting a different role of these miRNA in liquid tumours compared to their 
well-known pro-tumorigenic function in epithelial tumors The down-modulation of miR-
221/222 was also confirmed by the qRT-PCR method in a bigger cohort of BL cell lines 
compared to 4 normal B lymphoblast EBV transformed cell lines. The four cell lines 
representing the controls express high levels of miR-221 compared to the group that 
represents the BL cell lines where the miR-221 is lost. The same trend is shown for miR-222. 
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We found that interesting considering the up-regulation of miR-221 and miR-222 previously 
confirmed in a lot of solid tumors by multiple studies, such as breast, liver and lung cancer.  
Here, we are investigating a different role of the cluster 221/222 in lymphomas that have a 
different process in carcinogenesis than solid tumors. To better understand the potential 
role of miR-221/222 in BL, we also analyzed their expression levels in EµMyc transgenic 
mouse model which has been considered for a decade a good in vivo model of BL. We 
investigated the expression of miR-221 and 222 in B cells extracted from both transgenic and 
wild type mice. The miRNA levels detected by qRT-PCR show a down-regulation in 80% of 
the transgenic samples when compared to normal B cells derived from the spleen of wild 
type mice littermates.  
Once we determined that miR-221 and 222 were down regulated in both human and mouse 
models, we wanted to understand what pathways both of the models had in common and 
how miR-221 and 222 play a role in these pathways. Therefore, in order to establish the 
effect of miR-221 and 222 in a human model, we transfected BL cell line Bjab, which lacks of 
miR-221 and 222 expression with mature miRNA.  A gene expression analysis was then 
conducted on extracted RNA from treated Bjab cells collected 48 hours after transfection 
compared to its negative control collected at the same time point.  We then performed a 
parallel gene expression profile on the mouse model using the RNA extracted from CD-19+ 
of the wild type spleen and the transgenic spleen of littermates.  Then we picked the down-
regulated gene of the human gene expression profiling and compared it to the gene 
expression profile of the mouse model.  From this comparison, we found some genes that 
were up-regulated in the mouse model that were also down-regulated by miR-221 and 222 
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in the human model.   One of these genes is DUSP6/MKP-3, a MAP kinase phosphatase that 
dephosphorylate phosphothreonine and phosphotyrosine within ERK pathway, playing a 
role in the induction of apoptosis. This dual specificity phosphatase has been found also 
acting as an oncogene but no further studies have been conducted, leaving its function in a 
contradictory background. The level of expression in BL cell lines of DUSP6 has been 
evaluated by qRT-PCR, compared to negative lymphoblastoid cell lines and results show an 
up-regulation of the mRNA in 80% of BL cell lines whereas it’s lost in the controls, suggesting 
an oncogenic role of this protein in BL but additional studies need to be performed to confirm 
this hypothesis. 
Since these new findings may highlight a different role of these miRNA in BL compared to 
their well-known pro-tumorigenic function in epithelial tumors we cross a miR-221/222 KO 
mouse with the well-known EµMyc transgenic mouse model. The miR-221/222 KO doesn’t 
show any particular phenotype but when we breed the KO with the transgenic EµMyc we 
observe an early development of the BL pathogenesis in 5 out of 8 miR-221/222 KO/ EµMyc 
tg positive and death at 3-4 months of age while the wild type miR-221/222/ EµMyc tg are 
still alive at 6 months of age without showing any enlarged lymph nodes. Unfortunately, 
even these preliminary results indicate that the loss of miR-221/222 can play an important 
role in the pathogenesis of BL, the number of wild type miR-221/222 are not enough for the 
statistical analysis; for this reason we are increasing the numbers of litters and we need 
further investigations. 
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Our findings indicate that miR-221/222 can be critical mediators for BL pathogenesis and 
together with other important genetics alteration such as translocation of MYC can lead to 
the aggressive phenotype that this B cell malignancy usually shows. These results highlight 
the potential role of this cluster of microRNAs to be a good tool of diagnosis and prognosis 
for BL. 
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1.1 Burkitt Lymphoma 
 
 1.1a  History 
Burkitt lymphoma is a non-Hodgikin lymphoma that has had an important role in the 
understanding of tumorigenesis in recent years because of its genetic and molecular 
features1. Indeed, it was one of the first tumour shown to have a chromosomal translocation 
that activates a regular transcription factor to become an oncogene2. The disease is also 
associated with Epstein-Barr virus (EBV) and in fact it was the first tumor found to be 
correlated with a virus3, and the first lymphoma reported to be associated with HIV 
infection4. Burkitt lymphoma is a highly aggressive B-cell lymphoma and is considered the 
fastest growing human tumor, with a cell doubling time of 24-48 hrs, and was the first 
childhood tumor to respond to chemiotherapy alone5.  
Furthermore, it is the most common childhood cancer in areas where malaria is holoendemic 
and where there is an early acquisition of EBV—eg, equatorial Africa, Brazil, and Papua New 
Guinea6. Interestingly the epidemiological maps of these two diseases overlap7 and 
nowadays a Burkitt lymphoma belt has been defined which stretches across central Africa 
between latitude 15° on either side of the equator, where the climate is typically humid 
(more than 50 cm annual rainfall) and hot. Early in the 20th century, Sir Albert Cook, a 
missionary doctor in Uganda, and other medical staff working in west, east, and central 
Africa reported the high frequency of jaw tumors and childhood lymphomas8. Later on in 
1958, Denis Burkitt, an Irish surgeon working in Uganda, described cases of children 
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presenting with rapidly growing jaw or abdominal tumors9. At first Burkitt suggested that 
these tumors were round-cell sarcoma. However, in 1960 George O’Connor, a pathologist, 
concluded that the cancer was of lymphoma lineage10. In 1964, three virologists, Michael 
Anthony Epstein, Yvonne Barr, and Bert Achong identified viral particles in the tumor tissue; 
this virus became known as Epstein-Barr virus (EBV)3. Meanwhile, Burkitt travelled through 
eastern and central Africa to map the tumor spread and found records of affected children 
in all the malarial areas of the region11.  
 
1.1b  Classification 
Burkitt Lymphoma is listed in the World Health Organization (WHO) classification of 
lymphoid tumors as a single genetic and morphologic entity with variable clinical 
presentation. In particular, the WHO classification describes three different variants: 
endemic (eBL), sporadic (sBL) and immunodeficiency-related (HIV-BL). Each clinical subset 
affects different population and can present different features but they are similar in 
morphology, immunophenotype and genetic features. 
The endemic form is overall the commonest type; it is EBV infection associated in most cases 
and is consider a pediatric variant, being the most frequent childhood cancer in equatorial 
Africa. This variant is also correlated with malaria endemicity as well as with local 
environmental pathogens (ie, Euphorbia tirucalli) and coinfection with arbovirus also appear 
to be important for its pathogenesis. 
The sporadic variant is the predominant type found in non-malarial areas, whereas it occurs 
mainly in the rest of the world, especially in Europe and United States. This form doesn’t 
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have a special climatic or geographical link and is rarely associated with EBV infection; only 
20% of cases occurs concomitantly with Epstein-Barr virus infection. Sporadic BL also 
predominantly affects adults. 
The immunodeficiency-related BL subset is seen most often in patients affected by HIV and 
rarely in patients who have undergone organ transplantation12. In the latter case the risk 
increases 4/5 years after the transplantation, but still remains less than the risk associated 
with HIV. HIV-BL is more common in patients with relatively low CD4 counts which is a typical 
condition of the early stage of HIV infection. The immunosuppression itself however is not 
sufficient to explain the high prevalence of BL in this setting13. 
 
1.1c Epidemiology 
Nowadays in the United States, lymphoma is the most common form of blood cancer and it 
comprises over 5% of all cancers all over the world (Figure 1). Many forms continue to have 
5-year survival rates as low as 50% and require patients to undergo aggressive 
chemotherapies. 
The exact worldwide incidence of BL is not known due to the limited collection of 
epidemiologic data, which is in turn due to a lack of resources needed for case ascertainment 
and accurate diagnosis in the developing countries that have the highest apparent incidence 
(eg equatorial belt of Africa and New Guinea)14. 
As previously mentioned Burkitt lymphoma has been subdivided into three 
epidemiologically distinct forms, differing with respect to geographical distribution and EBV 
association15. 
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High-risk areas for Burkitt Lymphoma correspond to areas of equatorial Africa and New 
Guinea where malaria is holoendemic and there is an early acquisition of EBV. Here endemic 
BL accounts about half of all childhood cancers diagnosed with an estimated incidence at 40-
50 per million children per year16. The peak incidence occurs in children age 4 to 7 years and 
the disease is twice as common in boys as in girls. 
SBL is seen in low-risk areas such as North America, Europe and East Asia at an annual 
incidence of 2 per million children.  Though this form is found also in adults, it occurs most 
commonly in children of 6-12 years of age, affecting from 3 to 5 times more males than 
females17. 
Parts of South America, North Africa, southern Europe and Middle East are considered areas 
of intermediate risk. 
 
1.1d c-Myc translocation: the hallmark of Burkitt Lymphoma 
BL was the first type of cancer to be shown to have a chromosomal translocation that 
activates the transcription factor c-Myc to become an oncogene. This genetic rearrangement 
places Myc locus, which is usually on chromosome 8, under gene regulatory elements that 
lead to the overexpression of the protein c-Myc. All BL variants show high level of this 
transcription factor as a consequence of genomic aberration involving the chromosomes 14, 
2 and 22 where the DNA coding sequence of c-Myc is transposed under the control of 
immunoglobulin gene enhancers that are constitutively active in mature B cells (Figure 2). 
Translocation t(8;14) is the most common representing 80% of BL cases and it causes the 
overproduction of c-Myc under the control of the immunoglobulin heavy chain (IGH) 
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regulatory element on chromosome 14, resulting in a tumor promoting effect. In all other 
cases, c-Myc is translocated close to one of the immunoglobulin light chain genes on 
chromosome 2 (IGK- kappa light chain), resulting in the t(2;8) found in 15% of BL, or 22 (IGL- 
lambda light chain), resulting in the t(8;22) found in 5% of BL cases18 . The common effect of 
these translocations is that the juxtaposed c-Myc allele is expressed constitutively in tumor 
cells, as opposed to the strict regulation of c-Myc levels in normal B cells19 where it affects 
different pathways regulating cell cycle, growth, adhesion, differentiation and apoptosis.   
c-Myc rearrangements have been demonstrated for the first time in 198220 but in the last 
decade it has been shown that up to 5% of tumors with BL clinical, morphologic and 
immunophenotipic features lack of c-Myc translocation and its overexpression is due to 
other molecular mechanisms21. Other mechanisms leading tit h increased expression of c-
Myc include interference with the 5’ regulatory regions and/or stabilization of the protein 
product. 5’ regulatory regions normally present within the c-Myc DNA sequence can be 
mutated or moved as a direct result of the translocation. Liberation of c-Myc from normal 
regulation can result in increased expression of the protein. The c-Myc first exon/first intron 
border, where c-Myc regulatory sequences are located, can be either decapitated by the 
translocation described previously or undergo mutation in translocated alleles22.  
 
1.1e Other molecular mechanisms 
The overexpression of c-Myc via its juxtaposition with immunoglobulin gene enhancer 
induces genes like cyclin D2, TRAP1 and HLA-DRB, whereas others like p21 and platelet 
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derived growth factor receptor-alpha (PDGFRα) are consistently repressed, possibly playing 
a role in the pathogenesis of BL23. 
In addition to the presence of c-Myc translocations in the vast majority of BL cases, most 
tumors contain additional chromosomal abnormalities, the molecular implication of which 
are poorly understood24.   
Several studies have reported a high frequency of somatic mutations that appear to involve 
the transcription factor TCF3, its inhibitor ID3, or downstream targets (eg. CCND3)25-27. In 
one study authors report that approximately 70% of sBL cases had mutations in TCF3 or ID3. 
Mutations in CCND3 (a gene encoding cyclin D3, a key regulator of cell cycle progression) 
were present in 38 %25. 
Interestingly, in recent years, E2F1 was found to be overexpressed in most sBL. E2F1 is a 
member of E2F family of transcription factors that is involved in regulation of cell growth. 
Furthermore, reduction of E2F1 expression led to decreased growth capacity in sBL cells in 
vitro28. 
 
1.1f Epstein-Barr virus infection  
Epstein-Barr virus (EBV) is a member of the herpesvirus family, which includes herpes 
simplex I and II and varicella zoster virus, cytomegalovirus and human herpesvirus (HHV)-6-
7 and -829. EBV is one of the best understood of the human herpesvirus, for which there is 
an established biological model of infection and persistence. An icosahedral nucleocapsid 
and a tegument surround a DNA core that is contained in the enveloped virus. The EBV 
genome encodes for a series of products interacting with or exhibiting homology to a wide 
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variety of anti-apoptotic molecules, cytokines, and signal transducers, hence promoting EBV 
infection, immortalization, and transformation30,31.  
EBV has been strongly implicated in the endemic form of BL. Several observations suggest a 
direct causative role for EBV in endemic Burkitt’s lymphoma; monoclonal EBV infection is 
present in virtually all cases of eBL, approximately 30 percent of sporadic BL, and 40 percent 
of immunodeficiency-associated BL32. The pathobiologic role of EBV is poorly understood 
and the link in EBV- associated BL is less clear than with endemic BL. Most US cases of HIV-
associated BL are EBV-negative whereas the vast majority of HIV-associated BL in Africa are 
EBV-positive33,34. For example, EBV is consistently present in these tumours; infection of 
malignant B cells precedes tumorigenesis35; EBV induces immortalization of B cells in culture; 
and very high EBV antibody titers are recorded in children before development of the 
disease36. However, the underlying mechanism linking EBV infection of B cells to the 
emergence of malignancy remains undiscovered.  
One hypothesis is that EBV tends to cause a latent infection of B lymphocytes, some of which 
evade the T cell mediated immune response and enter the germinal center. This 
subsequently results in excessive B cell proliferation37 during which process translocations 
may occur, leading to overexpression of c-Myc. 
 
1.1g Clinical presentation 
The abdomen is the most common site of presentation in sporadic BL (60–80%)38. Presenting 
symptoms include abdominal pain (25% of patients have ileocaecal disease—either a right 
lower quadrant mass or pain from intussusception), distension, nausea and vomiting, and 
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gastrointestinal bleeding39,40. The next most common site is the head and neck, including 
lymphadenopathy and involvement of the nasal or oropharynx, tonsils, or sinuses. Rarely the 
jaw is implicated. Bone marrow is infiltrated only in 20% of patients. We observe also some 
cases classified as Burkitt’s leukaemia that are characterized by extensive marrow infiltration 
(more than 25% blasts), with possible bone pain as a common manifestation at the time of 
diagnosis. We can also find rare presenting sites include the mediastinum, CNS, skin, testes, 
breasts, and thyroid gland. Patients with endemic BL most frequently show with jaw or 
periorbital swellings, or abdominal involvement (of retroperitoneal tissue, gut, ovary, or 
kidney)41. 15% present with sudden paraplegia and incontinence. Infiltration of bone marrow 
is rare. Jaw involvement is common in young children (peak ages of incidence 3–7 years)42. 
It has been observed in low income regions, such as in sub-Saharan Africa, an advanced 
disease in many children. In a study of 84 Malawian children with BL, 26 (31%) presented 
with facial disease only and 52 (62%) with abdominal disease; 58 (69%) had St Jude stage III 
or IV disease41. 
 
1.1h Histopathology and immunohistochemistry 
BL is a highly aggressive B-cell non-Hodgkin lymphoma characterized by monomorphic medium-sized 
cells with a very high proliferation rate. The cells are intermediate in size and contain coarse 
chromatin and prominent basophilic nucleoli. Some plasmacytoid and atypical variants show more 
nuclear pleiomorphism. In tissue sections, typically the cells seem to be moulded and the cytoplasm 
is deeply basophilic with squared-off cytoplasmic margins. The proliferation index is almost 100%, 
with a high turnover shown by increased apoptosis. A “starry sky” appearance is due to scattered 
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tangible-body-laden macrophages that contain apoptotic tumour cells43. The cells are always of B-
cell lineage (CD20 positive and CD79a positive). CD10 and Bcl-6 are commonly coexpressed, but the 
cells are generally negative for Bcl-2. There is also a low number of T cells in the background44. 
Epstein-Barr-encoded RNA can be identified by fluorescence in-situ hybridization. Classification is 
difficult when the cells have the morphology of diffuse large B-cell lymphoma but the genetic and 
immune-phenotypic features of BL. Some of these cases are now classified as “B-cell lymphoma, 
unclassifiable, with features between diffuse large B-cell lymphoma and BL”. However, distinct 
molecular changes in BL could provide a more reliable diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
1.2 MicroRNA 
 
1.2a History 
In the traditional central dogma of molecular biology, the RNA molecule was considered just 
an intermediate of gene expression from DNA to protein. However, the finding of RNA 
interference involved RNA molecules in the regulation of gene expression.  
Small RNA molecules can bind to other specific RNAs and either decrease or increase the 
activity of the targeted RNAs. For example, small interfering RNA (siRNA) binds to specific 
target mRNAs, resulting in decrease of translation of the mRNAs45.  
The discovery in 1993 of a small endogenous regulatory RNA molecule in the nematode 
Caernorhabditis elegans (C. elegans) set the scenes for the description of a large family of 
short (≈22 nt) single-stranded ribonucleic acids termed microRNAs (miRNAs)46. Since the 
discovery, many microRNAs have been identified in most eukaryotic cells and have been 
considered critical posttranscriptional regulators of gene expression in complex life. It is not 
surprising, therefore, that miRNAs are themselves tightly regulated to allow the shaping of 
gene expression in a temporally restrained and tissue-specific manner instrumental for 
properly structured organismal development and growth47.  
To date it has been demonstrated in several studies that miRNAs participate in many cellular 
pathways and have provided many clues for missing part of cellular pathways48-51. 
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1.2b Canonical miRNA biogenesis  
The generation of miRNAs is a multistage process and takes place first in the nucleus and it 
continues in the cytoplasm (Figure 4). Long primary transcripts, called pri-miRNAs, are 
transcribed from genomic DNA by RNA polymerase II or III52. The majority of miRNAs are 
found in intergenic regions and for this reason the transcription of intergenic miRNAs is 
usually dependent on their own promoters. On the other hand, other miRNAs genes are 
located in protein-coding genes resulting in the name of intragenic miRNAs: this group is 
divided into exonic and intronic miRNAs based on their localizations. The expression of 
intragenic miRNAs depends on the promoter of their host genes52. The miRNA must 
therefore be excised during its biogenesis to cause gene silencing; two endoribonucleolytic 
enzymes are responsible for this excision. The first endonucleolytic reaction takes place in 
the nucleus and is driven by two proteins associated with each other; the transcribed pri-
miRs are processed to precursor miRNAs (pre-miRNAs) by the endoribonuclease Drosha in 
complex with the dsRNA binding protein DGCR8 (DiGeorge critical region 8). Drosha is a 
highly conserved 160 kDa protein containing two RNAse III domains and one double-strand 
RNA-binding domain. Drosha forms a huge complex, 500 kDa in Drosphila melanogaster (D. 
melanogaster) and 650 kDa in Homo sapiens, called Microprocessor and containing the co-
factor DGCR8. DGCR8, known also as Pasha in C. elegans and D. melanogaster, recognizes 
and binds to the double strand region of the pri-miRNA, functioning as a molecular ruler: 
DGCR8 arranges the Drosha cut site 11bp from the base of the hairpin stem. This progression 
releases a pre-miRNAs that possesses a 3’ extension. After being processed to pre-miRNAs, 
the precursors are exported to the cytoplasm via Exportin-5 (Exp5) in complex with Ran-GTP. 
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Once exported, the pre-miRNA is processed by a second endoribonucleolytic reaction, 
catalyzed by RNAse III Dicer53, which digests an ≈22nt RNA duplex with protruding 3’ 
projections at both ends. At this stage of the processing an Argonaute protein binds the 
duplex miRNA/miRNA* and one strand, complementary to the target mRNA (guide strand), 
is selected and subsequently forms the miRNA effector (mature miRNA) as part of the miRISC 
(miRNA-induced silencing complex). Whereas one of the two strands is selected as guide 
strand according to thermodynamic properties, the remaining strand, termed also as 
passenger strand or miRNA* (star miRNA; many publications refer to the two strand pair as 
miR-3p/miR-5p, referring to the direction of the functional miRNA)  is released and 
degraded. The so-called miRNA* was initially thought to be the strand subjected to 
degradation, while more recent evidences suggest that it does not simply represent a non-
functional bioproduct of miRNA biogenesis, but it can be selected as a functional strand and 
play significant biological roles54. Once the processing steps are completed, the mature 
single stranded miRNA product is incorporated in the complex known as miRNA-containing 
ribonucleoprotein complex (miRNP), or miRNA-containing RNA-induced silencing complex 
(miRgonaute or miR-RISC, a ribonucleoproteic complex containing Argonaute proteins, of 
which AGO1 and 2 have been the most widely studied. As a part of this complex, the mature 
miRNA is able to regulate gene expression at the post-trascriptional level, binding for the 
most part through partial complementarity to target mRNAs in mammals, and mainly leading 
to mRNA degradation or translation inhibition.   
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1.2c Alternative miRNA biogenesis pathways  
The two endoribonucleolytic cleavage steps represent the most obvious points at which 
functional miRNA production can be regulated. The first endoribonucleolytic digestion takes 
place in the nucleus as previously described and presents some unconventional processing 
steps of miRNAs.  
An alternative miRNA biogenesis pathway, called miRtron pathway, has been discovered 
among diverse mammals, drosophila and nematodes55-58: miRtrons are regulatory RNAs 
which get processed to form pre-miRs using the splicing machinery without Drosha-
mediated cleavage.  Moreover Drosha-DGCR8-mediated processing of let-7 pri-miRNA can 
be inhibited by Lin28B59, although the heterogeneous nuclear ribonucleoprotein A1 
(hnRNPA1) binds specifically to pri-miR-18a to promote its processing60. In the cytoplasm, 
Dicer catalyzes the second endonucleolytic reaction and is essential for miRNA maturation; 
it’s been also demonstrated that its knockdown in human cell lines marks the production of 
aberrant miRNAs61 and moreover the accumulation of pre-miRNAs.  
A number of recent reports have described regulatory mechanisms that affect on Dicer 
processing, labeling Dicer as a regulatory node in the cytoplasm. One such controlling 
pathway modifies via 3’end uridylylation of the pre-miRNA which alternatively promotes or 
inhibits dicing and the pre-miRNA maturation62,63 (Fig.4B). Dicer is a very large enzyme 
(approximately 200 kDa) which is conserved among the species and presents several 
different domains: a double strand RNAbinding domain (dsRBD); two RNAse III catalytic 
domains, one which binds the 30-end small RNAs (PAZ domain) and a second which binds 
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other domains with ATPasic and RNA-helicasic activity. Since Dicer does not function alone 
but in association with additional proteins (Fig.4C), such as TRBP (transactivating response 
RNA-binding protein) and PACT (protein activator of PKR), we find even more regulatory 
mechanisms at this level. TRBP and PACT interacting with Dicer may alter its activity to give 
different miRNA isoforms with new target specificities47.  
Furthermore, recent discoveries showed that members of the Argonaut family participate in 
the Dicer-mediated processing of pre-miRs, playing an important role in stabilizing the 
complex Dicer-miRNA64. In mammalians Ago2 protein complex, characterized by RNAse H 
activity, cooperates in the Dicer-mediated processing of some pre-miRNAs, yielding to 
another intermediate processing product, called AGO2-cleaved precursor miRNA (ac-pre-
miRNA)52. 
 
1.2d Mechanism of action and function of human microRNAs 
Once the microRNA processing steps are completed, the mature single stranded miRNA is 
integrated in the miRNP or miR-RISC complex to inhibit their target genes by pairing the 
3’UTR messenger RNA (mRNA). The mature form of miRNA is about 22 nucleotides long but 
only a small region of the non-coding RNA binds to its complementary sequence in the 3’UTR 
of the target gene: the 7-9 nucleotides from the 2nd to 8th (9th or 10th) nucleotide are 
identified as “seed region”65. The seed sequence has a major role in microRNA function and 
its interaction with 3’UTR target leads to repression of gene expression through three 
different mechanisms: (a) site-specific cleavage; (b) enhanced mRNA degradation; and (c) 
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translation inhibition. The first one is restricted to miRNAs with a prefect or near-perfect 
match to the target mRNA and it’s considered a very rare event in mammals, and it’s 
exclusively Ago2 dependent. The second and the third mechanisms just listed represent the 
common scenario in mammals and are frequently associated with mismatched 
miRNA/target sequences. Nonetheless the exact pathway through which miRNAs can impair 
translation is still debated, this mechanism together with the enhanced mRNA degradation 
are commonly defined as a non-cleavage repression, and can be carried out by any of the 
four components of the Ago family66. In addition, at this step we can find further pathways 
that can control the microRNA-mediated regulation of gene expression, like for example the 
formation of mRNA secondary structure capable of inhibiting the access of the target by the 
small non-coding RNA67. Likewise RNA binding protein can cover the complementary region 
of target mRNA by binding it and avoiding the microRNA seed sequence to pair with its target 
gene. Besides this canonical targeting regulation, more recent studies report that microRNA 
can also bind the 5’-untraslated region (5’ UTR) or the ORF68,69 and, even more remarkably, 
they can up-regulate translation upon growth arrest condition70. It is not surprising that each 
miRNA has the potential to target a large number of genes, since they are controlled by 
highly developed regulatory pathway and fine-tuning mechanisms in both miRNA processing 
and recognizing the target71-73. For this reason miRNAs are considered versatile regulators of 
gene expression and to date we can count roughly 60% of the mRNAs as sharing one or more 
sequences that are evolutionarily conserved and predicted to interact with miRNAs. 
Bioinformatics analysis predicts that 3’ UTRs of single genes are often targeted by several 
different miRNAs74. 
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1.2e microRNAs in cancer: oncogenes or tumor suppressors’ 
functional evidence  
Since their discovery in 1993 the role of microRNAs has been elucidated in various cellular 
pathways and diseases. For instance, members from the family of let-7 have been studied 
and found involved in several diseases such as asthma, hypertrophy, inflammation, 
Parkinson’s disease and various cancers75-77.  
Over the time, cancers develop refined networks of biological events allowing them to grow 
and, in some cases, escape treatment. In the pathogenesis of cancer, dysregulated miRNAs 
may function as either tumour suppressor or oncogenes (Figure 5) by targeting one of the 
six essential features of cancer progression described by Hanahan and Weinberg: self-
sufficiency in growth signals, insensitivity to anti-growth signals, apoptosis evasion, limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis78. 
Experiments of gain- and loss-of-function have provided new insights into the role of miRNAs 
in carcinogenesis. For example, tumour suppressor miRNAs have been studied through gain-
of-function approaches showing crucial roles in various cancer pathways by targeting 
oncoproteins such as BCL2, found regulated by miR-15a and miR-16-179, MYC or RAS, both 
targeted by let-780,81 and MCL1 (myeloid cell leukemia sequence 1) modulated by miR-29b82. 
Vice versa, to delineate the biological effects of oncogenic miRNAs, often overexpressed in 
cancer cells, in vitro silencing was performed using antisense oligonucleotides. For instance, 
a cohort of miRNAs such as miR-221, miR-222, miR-21, miR-24, miR-133, miR-17-5p, miR-19, 
miR-25 and miR-128 targets pro-apoptotic genes, resulting in inhibition of apoptosis.  
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The first examples of miRNAs with oncogenic activity validated in engineered animal models 
were miR-17-92 cluster and miR-155, both discovered to be over-expressed in lymph 
proliferative disorders, including lymphomas and leukemia83,84. Infection of murine 
hematopoietic stem cells with a retrovirus carrying the mir-17-92 cluster accelerated the 
development of lymphomas in Myc transgenic mice83. Two different studies describe the 
development of lymphoproliferative disease and autoimmunity in transgenic mice 
overexpressing miR-17-92 cluster in B cells85,86. Lymphocytes higher rate of proliferation and 
lower rate of activation-induced cell death in these mice were partially accredited to the 
direct targeting of the anti-apoptotic genes BIM and PTEN by miR-17-92 cluster. Moreover, 
Ventura and colleagues showed that mice deficient for miR-17-92 cluster died shortly after 
birth with lung hypoplasia and a ventricular septal defect85.  
Lastly, a subsequent study showed that deletion of the whole cluster miR-17-92 reduces 
Myc-induced oncogenesis87. In contrast, miR-155 overexpression in the lymphoid 
compartment was sufficient to cause cancer without any other cooperative mutation or Myc 
expression. Costinean and colleagues developed the miR-155 transgenic mice that showed 
polyclonal lymphoid proliferation followed by acute lymphocytic lymphoma or leukaemia88. 
These data were the first to report that the dysregulation of a single miRNA can lead to 
malignancy. Further, it was one of the first, and still few, miRNA engineered animal models, 
which, through knock out or transgene introduction, can provide the genetic demonstration 
of the causative involvement of a specific microRNA in a biological phenomenon. Regardless 
of notable recent studies in cancer-related microRNA, it is unlikely that miRNAs will be found 
responsible for a specific phenotype by aiming at a specific target. Though many critical 
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questions about microRNAs remain to be addressed, it is largely accepted that miRNAs 
engage in a complex interactions with the machinery that controls the transcriptome and 
simultaneously target multiple mRNAs. This is probably the most captivating foundation 
supporting the idea of using microRNAs as anticancer drugs. 
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1.3 Thesis significance 
 
The revolution in cancer research carried to a conclusion that cancer is, in essence, a genetic 
disease.  Alterations in three types of genes contribute to tumorigenesis: oncogenes, tumor-
suppressor genes and stability genes are considered responsible for initiation and 
development of cancer. Recent studies outlined miRNAs as an important stride in 
maintaining the balance among genes and regulating cell fate through critical mechanisms 
such as cell growth, cellular differentiation and programmed cell death. Imbalance in miRNAs 
expression levels has been shown to be a frequent hallmark in different human malignancies 
that can destabilize this equilibrium, thus contributing to cancer development and/or 
progression at different levels from initiation to metastatic disease. Data available to date 
clearly support the involvement of miRNAs in cancer etiology, and strongly suggest a possible 
use of these molecules as markers of diagnosis and prognosis, and eventually as new targets 
or tools for a specific therapy. Over the past few years miRNA signatures have been 
described to characterize different types of BL or to investigate the expression of miRNAs 
possibly regulated by c-Myc in BL cases positive or negative for Myc translocation. 
Furthermore microRNA expression profiles have been used to classify different types of BL 
from other lymphoma malignancies, such as different type of B cell Non-Hodgkin lymphoma 
(B-NHL), like B cell Chronic Lymphatic leukemia (B-CLL) or Diffuse Large B cell Lymphoma 
(DLBL). However, it remains unclear what the functional role of differentially expressed 
miRNAs is and no further studies have been conducted. 
30 
 
In the present thesis the reported researches focused on identifying the differentially 
expressed miRNAs in Burkitt Lymphoma using as control tissues extracted from lymph nodes 
of healthy patients. Previously, only T-cell have been used as negative control to compare 
RNA extracted from B cells obtained by BL patients. In this study we present a microRNA 
profile acquired by analyzing lymph nodes from BL patients and reactive lymph nodes from 
healthy patients or mononucleosis affected patients where by definition we can find a large 
cell population of B cells. 
In addition, the present thesis focused on miR-221/222, an important family cluster of 
miRNA previously described as oncogenes in solid tumours. We found this cluster to be 
interestingly down-regulated in BL and we investigated the role of miR-221 and miR-222 in 
both human and mouse models of BL. Many studies to date have been conducted on the 
role of miR-221/222 in cancer development, outlining the cluster as an oncomiR in solid 
tumors. Our hypothesis deviates from the theory developed in the last few years about the 
role of miR-221/222 in carcinogenesis, indicating that miRNAs’ function is extremely 
connected to cellular context. In fact, tumours can be mostly classified as liquid or solid and 
besides having diverse clinical and pathological features, they can have also different types 
of oncogenes, tumor suppressor genes and stability genes to be altered89. Liquid tumours 
include leukemias and lymphomas, are composed of neoplastic cells whose precursors are 
normally mobile. Solid tumours are composed of epithelial (epithelial tumors) or 
mesenchymal cells that normally are immobile. Liquid and solid tumours show numerous 
other differences, such as the number of mutations required to develop liquid or solid 
tumours. On the genetic level at last three mutations seem to be necessary to advance a 
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malignant solid tumour in adults90; in contrast, only one or two mutations may be required 
to develop a malignant liquid tumour91. For this reason also miRNAS can have multiple and 
conflicting roles in solid tumours than in liquid tumours. To date only one evidence show a 
down-regulation of miR-221/222, whereas the overexpression of miR-221/222 has been 
observed in a number of advanced malignancies, indicating that miR-221/222 could be 
potential therapeutic targets for epithelial cancer such as glioblastomas92, thyroid papillary 
carcinomas93, breast cancer94,95, hepatocellular carcinoma96 and, lung cancer97. These 
studies demonstrated that miR-221/222 overexpression has important consequences on the 
proliferation rate and the cell cycle distribution. Nonetheless lately also a downregulation of 
this family of miRNA encoded in tandem on the X chromosome in human, mouse and rat has 
been observed; in erythropoietic (E) culture of cord blood CD34+ progenitors cells, miR-
221/222 levels are markedly down-modulated, indicating that microRNA function depends 
on the cellular setting. In erythropoietic culture undergoing exponential cell growth, miR 
down-modulation is inversely related to increasing Kit protein expression. Treatment of 
CD34+ progenitors with miR-221/222 is able to induce impaired proliferation and increased 
differentiation of E cells. Likewise our study evidences a tumor suppressive role of the cluster 
221/222, indicating once more that microRNA function is exclusively dependent on the 
cellular context and tumour type. 
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Figure 1. Worldwide lymphoma-related mortality rates as reported by the World Health Organization 
according to data retrieved in 2009. This displays the estimated average number of deaths by country for every 
100,000 inhabitants. Notes: the data/color given for the following former countries were assigned as follows: 
"Serbia and Montenegro": Serbia, Montenegro. The following groupings/assumptions were made: France 
includes the overseas departments as well as overseas collectivities. The United Kingdom includes the Crown 
dependencies as well as the overseas territories. The United States of America includes the insular areas. The 
Netherlands includes Aruba and the Netherlands Antilles. Denmark includes Greenland and the Faroe islands. 
China includes the SARs of Hong Kong and Macao. 
Data retrieved: http://www.who.int/healthinfo/global_burden_disease/estimates_country/en/index.html 
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Figure 2. Chromosomal translocation occurring in Burkitt Lymphoma. 
In Burkitt Lymphoma overexpression of c-Myc is invariably connected to a chromosomal translocation of the 
Myc proto-oncogene to either chromosome 14, 2 and 22, harbouring the genes for the immunoglobulin µ (IGH) 
heavy chain and κ (IGK@) or λ (IGL@) light chains.  
Figure by (Klapproth and Wirth, 2010) 
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Figure 3. Burkitt Lymphoma “starry-sky” pattern. 
Low-power magnification showing sheets of uniform neoplastic cells with consistently scattered reactive 
tangible-body macrophages resulting in characteristic “starry-sky” appearance. Hematoxylin-eosin stain. 
Figure adapted from Molyneux EM, 2012 98 
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                 Figure 4. The Regulation of miRNA Function by Means of RNA Length. 
A. Canonical maturation pathway of miRNA 
B. Modification of the 3’ end of pre-miRNA by the untemplated addition of uridines catalized by 
cytoplasmatic TUTs. Mono-uridylylation facilitates Dicer processing, whereas Lin28 binding and oligo-
uridylylation are inhibitory. 
C. Tuning of Dicer cut-site selection (shifted by 1-2 nt) by its binding partners allows the generation of 
specific isomiRs with altered target specificities. 
D. Exonucleolytic 3’ trimming to the Ago-loaded mature miRNA alters the length and thus target 
specificity.  
Figure by (Yates et al., 2013) 
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Figure 5. MicroRNAs as oncogenes and tumour suppressor genes.  
MiRNAs can have oncogenic effects (oncomiRNA) when they target tumour suppressor genes. When an 
oncomiRNA is overexpressed, for example because the encoding gene is located in an amplified region of the 
genome, this will lead to down-regulation of the targets and to tumour formation (A). Conversely, a miRNA can 
be characterized by tumour suppressor properties if the main target in that specific cellular context is an 
oncogene; in this case, if the miRNA expression is lost, for example because the encoding gene is located in a 
deleted region of the genome, the resulting effect will be tumorigenic (B). In summary, what usually happens 
in a tumour is the over-expression of an oncogenic miRNA, and/or the loss of a miRNA with oncosuppressive 
properties. 
Figure adapted from Caldas C, 200599. 
  
37 
 
 
 
Chapter 2- Materials and 
Methods 
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2.1 Samples and reagents 
 
2.1a Patients 
Tissue specimens were obtained from the University of Bologna, Sant’Orsola-Malpighi 
Hospital. We examined 5 sporadic, and 2 endemic BL patients, compared to B cells from 
reactive lymph nodes of 9 healthy patients and 11 patients affected by mononucleosis. 
 
2.1b Cell lines 
All the cell lines used in this work were either purchased from the American Type Culture 
Collection (ATCC, Manassas, VA) or previously generated in Prof. Croce CM’s laboratory and 
kindly provided to me. Burkitt Lymphoma cell lines EBV positive (Daudi, Namalwa, Raji, EB3 
and P3HRI) and EBV negative (Loukes, BL41 and LY91) were obtained from ATCC. The cell 
line BJAB were obtained by Life Tecnologies. The cell line EW36 was derived from an 
American case diagnosed as undifferentiated lymphoma and EBV is not present in the 
tumour of origin, nor is found in the cell line but in certain respects displays the molecular 
features of eBL cases and it was formerly studied and well characterized100 by Prof. Croce’s 
group. RS11896, SK-DHL, REH and WNM of unknown EBV status were also obtained from 
ATCC. Lymphoblastoid cell lines (ADO cell lines) were made in Prof. Croce’s lab and obtained 
from peripheral blood lymphocytes of patients with Alzheimer’s disease by transformation 
with EBV following the protocol reported previously101. Pekarsky et al described and 
characterized ADO2069, ADO1476, ADO1471 and ADO1701 in their manuscript102. 
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Burkitt lymphoma cell lines, ADO cell lines and IM9 were grown in Roswell Park Memorial 
Institute 1640 (RPMI) medium, containing 10% heat-inactivated fetal bovine serum (FBS), 
2mM l-glutamine and 100 U/mL penicillin–streptomycin.  
 
2.1c Animals 
All animals were housed under specific pathogen free conditions and all experiments were 
performed according to animal use protocols and guidelines approved by the Ohio State 
University and approved by the Institutional Animal Care and Use Committee of the OSU 
Wexner Medical Center Comprehensive Cancer Center. 
The EµMyc tg mouse used for our in-vivo studies was purchased from The Jackson 
Laboratory company. The former name was C57BL/6J-Tg (IghMyc) 22Bri/J. First, the TgN 
(IghMyc) 22Bri transgenic strain was made in the laboratory of Dr. Ralph Brinster, University 
of Pennsylvania in collaboration with Dr. Alan Harris, currently of the Walter and Eliza Hall 
Institute of Medical Research, Melbourne, Australia. The transgene construct consists of the 
mouse Myc oncogene (c-myc) in association with Emu immunoglobulin heavy chain 
enhancer and Myc promoter. Expression of the mouse Myc is restricted to the B cells lineage. 
The strain was maintained by mating hemizygous male to a wild-type C57BL/6J female.  
For the validation of downregulation of miR-221 and miR-222 EµMyc tg mice and wild-type 
C57BL/6 littermates were sacrificed by cervical dislocation. Selected tissues (listed in the 
results section) were collected to purify B cells for subsequent RNA extraction. 
Constitutive miR-221/222 null mice were generated by a standard gene-targeting approach 
using the R1 embryonic stem cell line as previously described103,104 by Gianpiero Di Leva (data 
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unpublished) and kindly given to me. The miR-221/222-specific targeting vector was 
obtained by recombineering technology105. All the mice used in the experimental procedures 
were backcrossed at least four generations.  
 
2.1d RNA extraction protocols 
Recover all kit from Ambion was used to extract RNA from tissue paraffin embedded samples 
obtained from lymph nodes of cancer and healthy patients, following the manufacturer’s 
instructions. 
Total RNA from cell lines and B cells (CD19+) isolated from enlarged lymph nodes or spleen 
tissues collected from Eµ-Myc transgenic mice was isolated by TRIzol (Invitrogen) according 
to manufacturer’s instructions, starting from at least 1x106 cells. 
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2.2 Detection of microRNAs expression  
 
2.2a MicroRNA Expression arrays 
Microarray analysis was performed as previously described106. Briefly, 5 micrograms of total 
RNA were used for hybridization of miRNA microarray chips. These chips contain gene-
specific oligonucleotide probes, spotted by contacting technologies and covalently attached 
to a polymeric matrix. The microarrays were hybridized in 6X SSPE (0.9 M NaCl/60 mM 
NaH2PO4 ·H2O/8 mM EDTA, pH 7.4)/30% formamide at 25°C for 18 hrs, washed in 0.75X 
TNT (Tris·HCl/ NaCl/ Tween 20) at 37°C for 40 minutes, and processed by using a method of 
detection of the biotin-containing transcripts by streptavidin-Alexa647 conjugate. Processed 
slides were scanned using a microarray scanner (Axon), with the laser set to 635 nm, at fixed 
PMT setting, and a scan resolution of 10 mm. Microarray images were analyzed by using 
GenePix Pro and post-processing was performed essentially as described earlier107. 
Concisely, average values of the replicate spots of each miRNA were background-subtracted 
and subject to further analysis. miRNAs were retained when present in at least 20% of 
samples and when at least 20% of the miRNA had fold change of more than 1.5 from the 
gene median. Absent calls were thresholded prior to normalization and statistical analysis. 
Normalization was performed by using the quantiles method. MicroRNA nomenclature was 
according to the microRNA database at Sanger Center. Data analysis. F635-background 
values were used. Bad spots were removed. Non-Expressed spots were averaged for each 
gpr files (chip). For each mature miRNA, we computed the geometric mean of its multiple 
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reporters in the chip. A NaN value was assigned to miRNAs with more than 50% of corrupted 
spots, as reported by the GenePix image analysis software. All the results were log2-
transformed. The Normalization was performed by using the quantiles normalization, as 
implemented in Bioconductor "affy"" package108. We performed class comparisons 
algorithms in BRB-ArrayTools using the paired t-test (p < 0.05, FDR <0.05). Genes were 
considered statistically significant if their p-value was less than the chosen value of each 
analysis. A significance threshold was used to limit the number of false positive findings. 
Class comparison algorithms in BRB-ArrayTools were used to determine whether gene 
expression patterns could differentiate between lymphoma samples and controls109.  
 
2.2b Nanostring analysis  
The NanoString nCounter Human miRNA Expression Assay Kit was used to profile more than 
700 human micro-RNAs (miRNAs) in normal mammary gland or tumour tissues from MMTV-
HER2/neu mice (http://www.nanostring.com); 100 ng total RNA were used as input for 
nCounter miRNA sample preparation reactions. All sample preparation was performed 
according to the manufacturer’s instructions (Nano-String Technologies, Seattle, WA). 
Preparation of small RNA samples involves the ligation of a specific DNA tag onto the 3′ end 
of each mature miRNA. These tags are designed to normalize the Tms (melting 
temperatures) of the miRNAs as well as provide a unique identification for each miRNA 
species in the samples. The tagging is accomplished in a multiplexed ligation reaction using 
reverse complementary bridge oligonucleotides to direct the ligation of each miRNA to its 
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designated tag. After the ligation reaction, excess tags and bridges are removed, and the 
resulting material is hybridized with a panel of miRNA tag specific nCounter capture and 
barcoded reporter probes. Hybridization reactions were performed according to the 
manufacturer’s instructions with 5 μL fivefold diluted sample preparation reaction. All 
hybridization reactions were incubated at 64 °C for a minimum of 18 h. 
Hybridized probes were purified using the nCounter Prep Station (NanoString Technologies) 
following the manufacturer’s instructions to remove excess capture and reporter probes and 
immobilize transcript-specific ternary complexes on a sterptavidincoated cartridge. Date 
collection was carried out on the nCounter Digital Analyzer (NanoString Technologies) 
following the manufacturer’s instructions to count individual fluorescent barcodes and 
quantify target RNA molecules present in each sample. For each assay, a high density (600 
fields of view) was performed. The samples analyzed using the Nanostring technology are 
subject to lane-to-lane variations that can arise during processing. To minimize the impact 
of these sample preparation and detection anomalies, the data were normalized to the 
positive control count values. The positive controls are 63 synthetic miRNA sequences 
included in the assay to confirm successful ligation of the miRNA to the tags. This type of 
normalization is called “Technical Normalization”. Next,a biological normalization method 
“Quantile Normalization” has been applied108. To identify differentially expressed miRNAs 
between samples from twoclasses we used the non-parametric statistical test called 
Significance Analysis of Microarrays (SAM)110. SAM identifies miRNAs with statistically 
significant changes in expression by assimilating a set of miRNA-specific t tests. Once the set 
of significant (Positive and Negative) miRNAs have been computed, a cluster analysis has 
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been conducted to identify subgroups of significant miRNAs sharing a similar expression 
level. This has been done through the Average Linkage hierarchical clustering algorithm. 
These results have been obtained using the SAM and cluster analysis module of the Tmev 
(TM4) system111. 
 
2.2c Quantitative Real Time PCR 
Quantitative Real-Time PCR (qRT-PCR) was performed with the TaqMan PCR Kit (Applied 
Biosystems, Foster City, CA) according to manufacturer’s instructions, followed by detection 
with the Applied Biosystems 7900HT Sequence Detection System (Applied Biosystems). All 
reactions were performed in triplicate. Simultaneous quantification of 54 small endogenous 
nucleolar RNA U44/U48/U6 (for human samples) or snoRNA-135/snoRNA-234 (for mouse 
tissues) was used as a reference for TaqMan assay data normalization. The comparative cycle 
threshold (Ct) method for relative quantization of gene expression (User Bulletin #2; Applied 
Biosystems) was used to determine miRNA or mRNA expression level. For all the qRT-PCR 
experiments, values on the y-axis equal to 2−(ΔCt), where ΔCt is the difference between gene 
Ct and normalizer gene Ct. For quantification of DUSP6 mRNAs, the appropriate TaqMan 
probes were purchased from Applied Biosystems (Hs04329643_s1). Data were normalized 
using GAPDH or OAZ1. 
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2.3 Target identification and validation 
 
2.3a Transfection 
Bjab cell line was transfectd by electroporation using AMAXA 3D machine and supplies 
according to manufacturer’s instructions. Both the pre-miRNA molecules (Ambion) and the 
corresponding scrambled oligonucleotides, were transfected at a final concentration of 100 
nM, unless otherwise indicated and the transfection efficiency was greater than 95% for all 
the cell lines used. 
 
2.3b Mouse B cells purification 
Enlarged spleens, enlarged cervical, brachial or inguinal lymph nodes were isolated from 
EuMyc tg mice. Magnetic activated negative selection B-cell isolation kit was used to purify 
B cells from tissues (Miltenyi Biotec) after lysing red blood cells with 155 mM ammonium 
chloride.  
 
2.3c Gene expression profiles 
Total RNA was extracted with the use of the TRIzol reagent (Invitrogen and Life 
Technologies), purified with the use of the RNeasy Kit (QIAGEN), and processed according to 
the Affymetrix Expression Analysis Technical Manual. Fragmented cRNA (15 g) was 
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hybridized to HG-U133 2.0 Plus microarrays (Affymetrix). The gene expression values were 
determined by MAS 5 algorithm in Expression Console (Affymetrix), and normalization was 
performed by scaling to a target intensity of 500. The normalized data were managed and 
analyzed by BRBArrayTools Version 4.3.2. Affymetrix CEL files were imported and RMA 
normalized. Genes whose expression differed by at least 1.5-fold from the median in at least 
20% of the arrays were used. We performed class comparisons algorithms in BRB-ArrayTools 
using the paired t-test (p < 0.05).   
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2.4 Phenotyping 
 
At autopsy, selected tissues were immediately fixed in 10% (v/v) Gurr neutral buffered 
formalin (pH 7.4) for 48 hours before dehydration and embedding in paraffin wax. 5 µm 
sections from paraffin blocks were examined for histopathologic features: 2 sections per 
tissues were stained with Mayer’s haematoxylin and eosin. Tissue sections were examined 
by a clinical pathologist from Ohio State University Veterinary School experienced in the 
histological analysis of mouse tissues. For antibody staining, high-temperature antigen 
retrieval was performed overnight by incubating sections with 0.01 M citrate buffer. 
Endogenous peroxidase was quenched by 1% v/v H2O2 in PBS for 30 minutes. Sections were 
blocked with either goat or rabbit serum (10% v/v in PBS) depending on the host species of 
the secondary antibody. Primary antibodies were incubated for 1 hour at room temperature 
and were detected by HRP polymer anti-mouse or anti-rabbit Envision antibodies (DAKO). 
Sections were developed using DAB substrate (DAKO) then counterstained with Mayer’s 
haematoxylin.  
48 
 
2.5 Bioinformatics tools and statistical analysis 
 
miRNA nomenclature, sequences and related information: 
- Genome Browser: http://genome.ucsc.edu 
- miR Registry: http://www.sanger.ac.uk/Software/Rfam/mirna/ 
 
miRNA target prediction: 
- Targetscan: www.targetscan.org 
- miRGen Database: http://www.diana.pcbi.upenn.edu/miRGen.html  
- PITA: http://genie.weizmann.ac.il/pubs/mir07/index.html 
 
Statistical analysis:  
Two-tails Student's t-test was used to determine statistical significance and the P value was 
calculated for each experiment (p<0.05, p<0.01). 
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3.1 Downregulation of miR-221 and miR-222 in BL 
patients and human cell lines 
 
3.1a Introduction 
BL is a B-cell non-Hodgkin lymphoma (NHL) which has been characterized throughout the 
years based on a combination of clinical data and morphological, phenotypic and cytogenetic 
features. New, reliable markers continue to be required to improve the accuracy of 
lymphoma characterization, diagnosis and therapy selection. In the recent years, the 
discovery of a new type of non-coding small RNA, miRNAs, has given innovative impulse to 
cell differentiation and cancer pathogenesis studies49. MiRNAs post-trascriptionally regulate 
the expression of thousands of genes, including key genes in cell differentiation and cancer 
pathogenesis80. First evidence of the relationship between miRNAs and cancer arose with 
the description of the loss of miR-15/16 in CLL cases by researchers from Prof. Croce’s 
group112; since then, an increasing number of specific miRNA changes have been identified 
in many tumour types. The potential of using miRNAs for differential diagnosis of tumours 
and hematopoietic malignancies has been recognized in a numbered of disorders and it has 
been applied also to distinguish two different tumour types. For instance, in acute 
lymphoblastic and myeloid leukemias, the expression signatures of at least two of four 
microRNAs (miR-128a, miR-128b, miR-223 and let-7b) discriminated the two tumour types 
with about 95% of accuracy113. The importance of miRNAs as diagnostic markers in B-cell 
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lymphomas is linked to their role in cellular differentiation, as demonstrated in 
hematopoietic cells and for example, by miR-150, in B-cell differentiation114. Furthermore, 
altered miRNA expression profiles have been used to test whether different B-cell lymphoma 
types have specific miRNAs signatures, and to apply this knowledge to identify potential 
markers for distinguishing different types of B-cell non-Hodgkin lymphomas (NHLs)115. In BL, 
a prior study has demonstrated the value of c-Myc translocations throughout the expression 
of miRNAs possibly regulated by this gene in BL cases positive or negative for the 
translocation116. Mainly, Onnis et al identify miR-9* as potentially relevant for malignant 
transformation in BL cases with no detectable Myc translocation. Moreover microRNAs 
signatures in BL have been used to delineate the boundaries between this B-cell malignancy 
and other NHLs such as DLBCL115; these two different lymphoma types show different up-
regulated miRs, improving their classification among B-cell NHLs. Although in recent years 
there have been many significant developments in BL classification, additional molecular 
markers enabling a better distinction between BL and healthy patients is still needed.  
Here we show for the first time a microRNA signature acquired by analyzing and studying a 
group of BL patients compared to a group of healthy (non-cancer) controls. This is the first 
profile that has been prepared to described differences in miRNAs expression between 
disease and healthy in BL. Moreover we identify the down-regulation of a family/cluster of 
miRNAs previously defined as oncogenes. MiR-221/222 are strongly down-modulated in BL 
patients when we compared them to reactive lymph nodes from healthy patients. The same 
pattern of miR-221/222 expression is shown in BL cell lines, when related to their control 
(non-cancer), analyzed by nanostring and then confirmed by qRT-PCR. 
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3.1b Results and discussion 
To identify miRNAs that are deregulated in BL patients versus non-cancer patients, we used 
miRNA microarray analysis117 on a set of 2 eBL, 5 sBL, 9 reactive lymph nodes from non-
cancer patients and 11 lymph nodes from mononucleosis affected patients (non-cancer). 
RNA was extracted by paraffin-embedded lymph nodal tissues as described in chapter 2 
(Material and Methods). Interestingly all BLs were grouped within one cluster, presenting 
with relatively homogeneus profiles for both upregulated and downregulated miRNAs 
(Figure 6). Furthermore, the two heat maps in figure 6 also show all non-cancer samples 
clustering together, presenting a distinguished miRNA expression signature differing from BL 
cluster. Apparently, such intriguing result is not related to EBV status since in both cancer 
and non-cancer groups we observed the same trend of miRNA expression whether the 
sample is negative or positive for EBV infection. Indeed in BL cluster we found that each 
downregulated or upregulated miRNA has the same pattern in both EBV negative (sBL) or 
EBV positive (eBL) patient samples. Likewise reactive lymph nodal tissues (EBV negative) 
clustered together with mononucleosis affected lymph nodes (EBV positive). The link 
between EBV infection and BL is strong, but the mechanism underlying that association is 
still unclear because conflicting hypotheses have been described throughout the years. A 
recent study compared gene expression profiles among BL subtypes, including endemic, 
sporadic, and HIV-associated BL samples. Although the BL samples were clearly distinct from 
other B-cell malignancies, distinguishing among BL subtypes was less precise and the 
samples did not cluster according to EBV status118.  In our research we show a microRNA 
profile that is not related to EBV infection indicating that the virus is not contributing to the 
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microRNA pattern and the role of EBV in BL pathogenesis needs further investigations.  
Indeed, we observed copious miRNAs down-modulated like for example miR-23a, let-7a, 
miR-96, miR-24, miR-29a, miR-182, miR-146a, miR-21, miR-101 and miR-22 in all cancer 
patients compared to healthy controls where all previously listed miRs are up-modulated. 
We also found many miRNAs upregulated in the “tumour” cluster related to their expression 
in “non-tumour” cluster, as miR-9, miR-122, miR-17 and miR-579. Among the 
downregulation of several miRNAs we identified an important miRNA which has been 
described already involved in several solid tumours, miR-221.  MiR-221/222 are encoded in 
tandem on the X chromosome in human, mouse and rat and are highly conserved in 
vertebrates93. Moreover, they have the same seed sequence97. In accordance with current 
literature, many studies have been reported on the role of miR-221/222 in cancer 
development as oncomiR and only in few cases as oncosuppressor-miR119,120. 
Overexpression of miR-221/222 has been observed in a number of advanced malignancies 
indicating that miR-221/222 could be potential therapeutic targets for epithelial cancers121. 
In our research we observe the downregulation of miR-221, suggesting a different role than 
the one formerly defined in multiple studies on solid tumours, like for example lung, liver 
and breast cancer. We found this new finding innovative considering that to date only two 
studies support the hypothesis of the cluster 221/222 to play an oncosuppressive role119,120. 
Our study could be added to these previous indications, leading to the theory that microRNA 
function depends on the cellular context.  After identifying a downregulation of miR-221 by 
microarray analysis (Figure 7) in human samples we investigate the pattern of miRNAs 
expression also by nanostring analysis in two different sets of BL cell lines compared to their 
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controls. We divided human BL cell lines in two different groups according or not to EBV 
presence. MiRNAs expression of five EBV positive BL cell lines (Daudi, Namalwa, Raji, EB3 
and PH3RI) was compared to five ADO cell lines, B lymphoblastoid cells EBV transformed 
(IM9, ADO2069, ADO1471, ADO1476, ADO1017), whereas miRNAs level of five EBV negative 
BL cell lines (BJAB, Loukes, BL41, LY91 and EW36) was related to their negative control, 
CD19+ B cells (EBV negative). A similar pattern of expression was identified between the two 
nanostring analyses (Figure 8) and moreover we found some miRNAs downregulated in 
common with the microRNA signature. For instance miR-101 and miR-29a are shown to be 
downregulated in both custom microarray platform analysis and EBV negative set of BL cell 
lines comparison; whereas we detected low expression of miR-22, miR-146a, miR-23a, miR-
21 and miR-24 in EBV positive BL cell lines set of nanostring investigation in common with 
our microarray signature. MiR-221 and miR-222 are identified downregulated in EBV positive 
BL cell lines compared to EBV positive lymphoblastoid cell lines and miR-222 is found 
downregulated in nanostring analysis of EBV negative BL cell lines cluster. The down-
regulation of miR-221/222 was further confirmed by the qRT-PCR method in a bigger cohort 
of human BL cell lines (Namalwa, Raji, Bjab, RS11896, SK-DHL, EW36, REH, WNM, EB3, 
Louches, BL41, PH3RI, Daudi) compared to 4 normal B lymphoblast EBV transformed cell 
lines (Figure 9). Moreover the statistical analysis established that miR-221/222 are down-
regulated in Burkitt Lymphoma’s cell lines compared to normal control with Fold Change 
miR-221=-33.85, miR-222=-134.80 and p-value for both: P<0.01. 
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3.2 BL in-vivo model shows down-modulation of 
miR-221/222 
 
3.2a Introduction 
MicroRNAs as a new class of regulatory molecules have been investigated in many specific 
cells and organs in healthy and diseased conditions in several types of tumours. These small 
non coding RNAs are known to play significant roles in animals and humans at the post-
trascriptional level and miRNAs signatures have been described in in-vivo model of severe 
diseases such as pancreatic cancer122 and gastric cancer123. Several mouse models have been 
created to mimic human malignancies and most of them have been proven useful for 
studying tumour progression, prevention and therapy. Recent reports from Ali et al and Shah 
et al showed that expression profiles of miRNAs in mouse models of respectively pancreatic 
and gastric cancer can be highly informative in discriminating the malignant from the normal 
because of the unique patterns of expression of miRNAs of their in-vivo models. These 
findings indicate the significance and untapped potentiality of comparing miRNAs level in 
both human and engineered mouse models which emulate genetic alterations found in the 
corresponding human anomalies. We assessed miRNAs signatures in patients’ paraffin 
specimens from lymph nodes and in BL human cell lines, finding a down-regulation of miR-
221/222. For a better understanding of our miRNAs’ contribution to BL we screened the level 
of miR-221 and miR-222 in a well-known mouse model of BL. Previously in Chapter 1 
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(introduction), we discussed how chromosomal translocation juxtaposing the MYC 
protooncogene with regulatory sequences of immunoglobulin (Ig) H chain, on chromosome 
14, or kappa (Igκ), on chromosome 2, or lambda (Igλ), on chromosome 22, chain genes and 
effecting deregulated expression of Myc are considering the hallmarks of human BL. The 
renowned mouse model described for the first time in 2000 and considered the most 
suitable system to study the pathogenesis of BL used the foundation of the genetic hallmark 
for BL124. A BL with striking similarities with the human BL develops in mice bearing a 
mutated Myc gene controlled by a reconstructed Igλ locus including all the elements 
required for establishment of locus control in vitro. Since studying miRNA expression levels 
in mouse models of human malignancies has been previously described to be fundamental 
in characterizing the molecular basis of the human disease, we investigated expression level 
of miR-221/222 in transgenic mice EµMyc. In summary here we propose a new role for the 
cluster 221/222 after examining a miRNAs signature in BL for the first time compared to 
“cancer-free” controls in a human model which is also confirmed in a recognized engineered 
in-vivo model of BL. 
 
3.2b Results and discussion 
We used a mouse model of BL purchased from the Jackson Labs (description in Chapter 2) 
where expression of the mouse Myc transgene is restricted to the B cell lineage. The 
literature reporting this in-vivo model of BL showed that hemizygotes have increased pre-B 
cells in the bone marrow throughout life and a transient increase in large pre-B cells in the 
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blood at 3-4 weeks of age. Spontaneous pre-B and B cell lymphomas reach an incidence of 
50% at 15-20 weeks in hemizygous progeny of a wildtype female mated with a hemizygous 
male.  Before checking the expression of the cluster 221/222 in the mouse model we 
characterize and analyze the phenotype of our in-vivo model of BL. We analyze two different 
transgenic mice of 6 months old, one female and one male. We observed that the massive 
enlargement of lymph nodes and spleen (Figure 10) coupled with widespread involvement 
of kidney, liver, and lung is consistent with widespread BL with leukemia. The primary cellular 
traits of the neoplastic lymphocytes appeared to represent a middle ground between images 
of BL and Burkitt-like lymphoma as reported in a recent proposal on the nomenclature for 
lymphoma in mice125. However, the distribution of tumor cells at various sites and the 
extensive apoptosis (“starry sky” phenotype) closely resembled images of BL in Myc-
transgenic mice124. The tumor cells expressed the B-cell marker B220 but were not producing 
the T-cell marker CD3.  We used B cells negatively selected as described in Chapter 2 
(Materials and Methods) collected from enlarged lymph nodes and spleens from six EµMyc 
transgenic mice to validate miR-221 and miR-222 expression patterns. The expression data 
were compared to B cells isolated from the spleen of three wild-type littermate mice; the 
relative expression of miR-221/222 is strongly down-regulated in 13 out of 17 samples 
obtained from transgenic mice when we evaluate the data sets with the expression of B cells 
from wild-type mice (Figure 11). To note that we didn’t compare the transgenic group of 
samples to lymph nodes from wild type mice because these small lymphatic organs are often 
difficult to identify in mice using standard dissection techniques. In facts while enlarged 
lymph nodes can be readily identified in mice with acute inflammation or advanced cancer, 
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the lymph nodes of normal mice are small and difficult to distinguish from surrounding 
adipose and connective tissue126. 
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3.3 Gene expression profiles in human and mouse 
models of BL identify DUSP6 as common target 
 
3.3a Introduction 
Over the past years gene expression profiling has been shown to be a powerful tool that can 
be used to classify, clarify the origins, and potentially even identify the underlying causes of 
malignancies. In the field of molecular biology, this technology is defined the measurement 
of the activity (expression) of thousands of genes at once, to create a global picture of cellular 
function. The first profiles were shown in early 2000 and if reliable, microarrays could be 
used for anything from testing a drug’s effect to identify differential pathways involved in 
two or more diverse experimental conditions127. In the understanding of BL pathogenesis we 
identify two pioneering studies published in 2006 which used gene expression profiling to 
define a molecular BL phenotype that would aid accurate diagnosis128,129. They both 
investigated the gene expression patterns in classical BL, atypical BL (DLBCL with BL-like 
characteristics, in terms of either c-myc/Ig translocation or immunophenotype) and typical 
DLBCL. Since BL and DLBCL require different treatment regimes, they assessed through gene 
expression profiles a molecular BL phenotype that could clarify their diagnosis. Using 95% 
similarity to consensus molecular BL gene signature as the standard, all classical BLs and 
most all atypical BLs displayed a molecular BL phenotype; correspondingly, the molecular BL 
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signature differed from that of typical DLBCLs by mainly relative up-regulation of c-myc 
target genes. Nevertheless, these revolutionary studies focused on only European and North 
American tumours, and the EBV status was neither specified nor taken into consideration for 
the analysis. Concerning the importance of EBV infection in understanding the molecular 
phenotype of BL, more recent work suggests that endemic BL tumours are broadly similar to 
sporadic tumours in gene expression profiles indicating that all BL subtypes converge on 
gene expression profiles that are highly connected and lie within the restricted molecular BL 
boundary. The last gene expression signature in BL has been conducted to gain further 
understanding in two types of endemic BL which display different patterns of EBV antigen 
expression and, by implication, arise by different pathogenic routes130. Kelly et al concluded 
that the two types of endemic BL show only slightly distinct phenotypes and both display 
gene expressions profiles that fit within the molecular BL defined boundary. Furthermore, 
we can find in gene expression profiles’ history of BL a study which demonstrates a shared 
gene expression signature in mouse models of EBV-associated and non-EBV-associated BL to 
elucidate the mechanism underlying the link between EBV and BL pathogenesis131.  
Though a few gene expression profile’s discoveries have been made throughout the last 
decade, whether there are patterns within the molecular BL signature that distinguish 
precise pathways of BL pathogenesis remains to be determined.  
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3.3b Results and discussion 
Once we established that miR-221 and 222 were down-regulated in both human and mouse 
models, we wanted to understand what pathways both of the models had in common and 
how miR-221 and 222 played a role in these pathways. Therefore, in order to establish the 
effect of miR-221 and 222 in a human model, we transfected BL cell line Bjab, which lacks of 
miR-221 and 222 expression, with the mature form of both miRNAs (as described in Chapter 
2, Materials and Methods).  A gene expression analysis was then conducted on extracted 
RNA from treated Bjab cells collected 48 hours after transfection compared to its negative 
control collected at the same time point. As shown in figure 13, we analyzed comparative 
expression levels of both miR-221 and miR-222 at 24 hours, 48 hours and 72 hours’ time 
points after transfection and the time point showing the highest expression levels of both 
miRs is at 48 hours; this time point was selected to establish the gene expression profile. 
Subsequently we performed a parallel gene expression profile using the mouse model; we 
compared the RNA extracted from CD-19+ of the wild type spleen with the RNA extracted 
from CD19+ of the transgenic spleen of littermates.  Then we picked the down-regulated 
gene of the human gene expression profiling and compared it to the gene expression 
profiling of the mouse model.  From this comparison (Figure 12), we found some genes that 
were up-regulated in the mouse model that were also down-regulated by miR-221 and 222 
in the human model, to indicate their candidacy to be targets of miR-221/222. One of these 
genes is DUSP6/MKP-3, a MAP kinase phosphatase that dephosphorylates 
phosphothreonine and phosphotyrosine within ERK pathway, playing a role in the induction 
of apoptosis. This dual specificity phosphatase has been found also acting as an oncogene 
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but no further studies have been conducted, leaving its function in a contradictory 
background. Before performing the experiment for the validation of Dusp6 as target of miR-
221/222 we first investigated if this protein was listed as expected target by bioinformatics 
prediction analysis. The binding site for miR-221-3p in DUSP6 3’UTR was predicted by the 
computational tool PITA (figure 14). Since miR-222 has the same seed of miR-221 because 
are from the same family, the target prediction is also effective for miR-222. The level of 
expression in BL cell lines of DUSP6 has been evaluated by qRT-PCR, compared to negative 
lymphoblastoid cell lines and results show an up-regulation of the mRNA in 80% of BL cell 
lines whereas it’s lost in the controls (Figure 15). To better understand the role of DUSP6 in 
BL we are planning to conduct further studies and using different methods such as WB in BL 
cell lines, qRT-PCR and WB in B cells extracted from lymph nodes of transgenic mice 
compared to their wild type littermates, immunohistochemistry in both human and mouse 
lymph nodes to check the expression of the protein in the specific tissue and the luciferase 
assay, to confirm Dusp6 as a target gene of miR-221 and miR-222. 
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3.4 Constitutive knock-out miR-221/222 in vivo 
model can anticipate BL pathogenesis in EuMyc 
tg mouse model: preliminary data 
 
3.4a Introduction 
The discovery of microRNAs (miRNAs) has revealed a new level of gene expression regulation 
that affects many normal and unusual biological pathways. MiRNAs are thought to have 
tumor suppressive or tumor promoting properties, depending on the nature of their specific 
targets and countless malignancies have been found affected by the dysregulation of 
miRNAs. In the last 6-7 years, the experimental field that provided the deepest insights into 
the in vivo biology of miRNAs is that of mouse modeling in which transgenic and knockout 
animals mimic, respectively, over-expression or down-regulation of specific miRNAs involved 
in human malignancies. The first in vivo evidence that microRNAs are essential in the 
development process came from the generation of the miRNA-processing factors Dicer, 
DGCR8, Drosha and AGO2 knockout mice. These mouse models, lacking these key miRNA 
processing genes, died indeed during early gestation with severe developmental defects132-
134. Individual miRNA knockouts were first reported in 2007 by four independent groups135-
138. Following these initial discoveries, the number of miRNA knockouts generated has 
critically increased. Observations from published knock-out mouse models suggest that 
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miRNAs can control expression of numerous functionally related proteins to apply their 
biological functions and these mechanisms of action may vary from one miRNA to another, 
over the course of development, or in a tissue-dependent manner139. Although these and 
others knock-out studies clearly demonstrated the importance of miRNAs on specific 
developmental stages and tissues, it is not clear which miRNAs are responsible for the 
observed phenotypes. 
 
3.4b Results and discussion 
To further explore miR-221/222 function in the biology of Burkitt Lymphoma development 
and its involvement in the tumourigenesis process, mice with constitutive loss-of-function 
alleles for miR-221/222 were crossed with EµMyc mice in collaboration with Gianpiero Di 
Leva from Prof. CM Croce’s laboratory. The miR-221/222 KO doesn’t show any particular 
phenotype (data unpublished) but when we breed the KO with the transgenic EµMyc (Figure 
17) we observe an early development of the BL pathogenesis in 5 out of 8 miR-221/222 KO/ 
EµMyc tg positive and death at 3-4 months of age while the wild type miR-221/222/ EµMyc 
tg are still alive at 6 months of age without showing any enlarged lymph nodes (Figure 18). 
Unfortunately, even these preliminary results indicate that the loss of miR-221/222 can play 
an important role in the pathogenesis of BL, the number of wild type miR-221/222 is not 
enough for the statistical analysis; for this reason we are increasing the numbers of litters 
and we need further investigations. 
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Figure 6. BL has a unique miRNAs signature distinct from healthy (non-cancer) patients. The unsupervised 
hierarchical clustering, based on the expression of almost 900 miRNAs, clearly separated BL patients from the 
“healthy” (cancer free) patients, in particular grouping eBL cases with sBL cases and reactive lymph nodes from 
cancer free cases with lymph nodes from cancer free mononucleosis cases. The dendograms were generated 
with the use of a hierarchical clustering algoritm that was based on the average-linkage method. In the matrix, 
each column represents a sample and each row represents a miRNA. The color scale bar shows the relative 
gene expression changes normalized by the standard deviation (0 is the mean expression level of a given 
A
t
B
t
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miRNA). Dendogram A shows the miRNAs downregulated (green) in BL versus non-cancer patients, whereas 
dendogram B shows the miRNAs upregulated (red) in BL versus non-cancer patients. Observing both heat-
maps, at the cut-off of 0.05, there is a homogeneous expression pattern of disregulated miRNAs between the 
tumor samples and the negative controls. 
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Figure 7. Down-regulation of miR-221 found in the microarray profile. Magnification of the dendogram in 
figure 6A to illustrate that miR-221 is among the most down-regulated miRNAs in BL patients cluster compared 
to non-cancer cluster. The color scale bar shows the relative gene expression changes normalized by the 
standard deviation (0 is the mean expression level of a given miRNA). 
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Figure 8. Nanostring analysis on two different sets of BL cell lines compared to their controls, respectively 
CD19+ B cells (EBV negative) or ADO cell lines (EBV positive). miRNA expression patterns analyzed by 
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nanostring analysis in a cohort of 5 EBV negative BL cell lines (BJAB, Loukes, BL41, LY91 and EW36) compared 
to 5 CD19+ B cells (top chart) and in a second cohort of 5 EBV positive BL cell lines (Daudi, Namalwa, Raji, EB3 
and P3HRI) compared to EBV transformed B lymphoblastoid cell lines (IM9, ADO2069, ADO1471, ADO1476, 
ADO1701). 
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Figure 9. qRT-PCR on a cohort of human BL cell lines compared to ADO cell lines (EBV positive). Comparative 
level of expression of miR-221 (top chart) and miR-222 (bottom chart) in the same cohort of human BL cell lines 
(EBV positive, EBV negative and unknown EBV status) compared to 4 B lymphoblastoid EBV transformed cell 
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lines. Data are mean of three replicates for each sample and each sample is compared to the highest expression 
level found in the controls. For miR-221, each comparative level of expression for each sample is compared to 
the level of expression of IM9, whereas for mir-222 expression, we compared to the level of expression of 
ADO2069. 
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Figure 10. Characterization and phenotypic analysis of one of the EµMyc transgenic mouse from the case 
selection used in our qRT-PCR analysis to assess level of miR-221/222. The primary gross findings (A) were 
massive enlargements of all lymph nodes (lymphadenopathy) and the spleen (splenomegaly [sp]). Visible lymph 
nodes are identifying by letters B= brachial, I=inguinal, S= superficial cervical. The pleural plaque of neoplastic 
lymphocytes (B) stained with H&E illustrates the closely packed, dark basophilic traits of most neoplastic 
lymphocytes (top) as well as the unusual appearance of a small population of large, loosely attached, pale 
eosinophilic lymphocytes (bottom). Enlarged lymph node were filled with continuous sheets of neoplastic 
lymphocytes (H&E, panel C). Apoptosis of the tumour was widespread, typically occurring in clusters (scattered 
A B 
C D 
E 
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clear spaces, termed a “starry sky” appearance). Cancer cells expressed B-lymphocytes marker B220 (IHC, panel 
D) but did not produce the T-lymphocytes marker CD3 (IHC, panel E). B magnification: 400X. C-E magnification: 
100X  
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Figure 11. Down-modulation of miR-221/222 in EµMyc transgenic mice, in vivo model of BL.  qRT-PCR analysis 
showing level of expression of miR-221-222 in a panel of  17 samples taken from 6 different  EµMyc tg mice 
and compared to their controls:  three spleens  obtained from  wild type littermates. Data are mean of three 
replicates per sample and each sample is compared to the expression level of spleen number 3 from the 
negative controls cluster.  
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Figure 12. Comparison of gene expression profile in a human BL cell line upon 48 hrs transfection of miR-
221/222 and gene expression signature in EuMyc tg mice. Gene expression patterns in two different systems: 
the cluster dendogram A represents the microarray analysis performed on RNA extracted from a BL cell line 
BJAB (which lacks of miR-221/222 expression) after reestablishing the level of the two miRNAs, whereas the 
cluster dendogram B represents the gene expression profile of B cells samples purified from spleen of EuMyc 
tg mice. For both analyses we used 4 replicates of each condition: in dendogram A we evaluated the differential 
expression of genes after 48 hrs of mature miRNAs transfection and we used 4 different replicates for each 
transfection (scramble (control oligo), mature miR-221 and mature miR-222); in dendogram B instead we 
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analyzed spleens from 4 EuMyc tg mice and 4 WT littermates. If we compare downregulated genes upon re-
expression of miRs in human BL cell line with upregulated genes in BL mouse model, where we previously 
showed having a down-regulation of miR-221/222, we find DUSP6 as common target. 
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Figure 13. q-RT PCR showing expression levels of miR-221/222 upon transfection. Comparative level of 
expression of miR-221 and miR-222 in BJAB cell line (which lacks of miR-221/222 expression) after restoring 
their level through transfection of the mature miRs. At 48 hrs after reestablishing their levels, we see the 
highest level of expression for both miRs. This time point was used to perform the gene expression profile 
shown in figure 12 (dendogram A). 
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Figure 14. Seed sequence of miR-221 and its binding to 3’UTR of target mRNA Dusp6. Schematic 
representation of the interaction between miR-221 and the binding site on the wild type DUSP-6-3’UTRThe 
binding site for miR-221 in DUSP6 was predicted by the computational tool PITA. This software is based on the 
structural accessibility of the target mRNA. It computes the difference between the free energy gained from 
the formation of the microRNA-target duplex and the energetic cost of unpairing the target to make it 
accessible to the microRNA. PITA was able to find a 6mer site on both isoforms of DUSP6 (NM_001946, 
NM_022652). The predicted interaction is shown in figure. 
 
Organism RefSeq me microRNA Position Seed dGduplex dGopen G Conservation 
Human 
NM_001946; 
NM_022652 
SP6 hsa-miR-221-3p 797 6mer -9.4 -4.76 -4.63 0.46 
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Figure 15. Comparison between comparative expression of miR-221 and miR-222 detected by qRT-PCR and 
expression level of DUSP6 detected by qRT-PCR.  Comparative level of expression of miR-221 and miR-222 
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shown in the same chart (top graph) and previously described in figure 9, to be related to comparative level of 
expression of DUSP6 in the same cohort of BL cell lines. Statistical analysis: miR-221/222 are down-regulated 
in Burkitt Lymphoma’s cell lines compared to normal control (Fold Change miR-221=-33.85, miR-222=-134.80, 
P<0.01); DUSP6 is up-regulated in Burkitt Lymphoma’s cell lines compared to normal control (Fold Change 
DUSP6=+5, P<0.05). 
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Figure 16. Schematic view of miR-221/222 knockout generation. Schematic representation of miR-222/221 
null allele.  MiR-222/221 have been replaced by the Neo cassette. Strategy of cloning: right and left arm were 
amplified from mouse genomic DNA and cloned in the TOPO-TA vector where the loxP-Neo-loxP cassette was 
previously cloned in EcoRI restriction site. Both probes for southern blot analysis at the 5` and 3` arms are 
reported and are represented by red boxes. 
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Figure 17. Breeding strategy. The picture shows the breeding approach applied to study the role of miR-
221/222 downregulation in vivo. A female miR-221/222 null mouse was bred with a male which is a well-known 
model of BL in vivo, the transgenic mouse for Myc. In our study we used only males of the first generation: 
since miR-221/222 cluster is on X chromosome the males obtained were either homozygous for miR-221/222 
WT or miR-221/222 null whether instead at the first generation of females we had only heterozygous miR-
221/222 null.  
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Figure 18. Survival rates of miR-221/222 null/EµMyc tg mice compared to their WT littermates. Graft showing 
the Kaplan-Meier survivorship curve, with conversion to death as the endpoint. The survival rate of the control 
group (miR-221/222 WT- tg Eµ-Myc) is represented by only two cases (blue bars) and it’s not enough to have a 
statistical significance but indicates the importance of the ablation of miR-221/222 as an important event that 
contributes to the aggressiveness of the disease and its progression. “Steps” in the survival curve indicate the 
occurrence of the permanent failure (death). 
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Chapter 4-Conclusions and 
future directions  
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Here, we studied for the first time the miRNAs expression signature of BL subtypes compared 
with normal B lymphocytes obtained from reactive lymph nodes of cancer free patients. 
First, we showed that BL is a distinct entity, supporting the current WHO classification. In 
fact, we showed that the miRNAs profile of all BL subtypes is quite homogeneous and distinct 
from those of cancer free lymph nodes. In addition, significantly, we showed that the 
described BL microRNAs signature is not related to EBV infection. Moreover, we are 
reporting that miR-221 and miR-222 are significantly down-regulated in BL when compared 
to healthy (cancer free) controls. These new findings may highlight a different role of 
these miRNA in lymphoma cells compared to their well-known pro-tumorigenic function in 
epithelial tumors. To better investigate the potential role of miR-221 and miR-222 in Burkitt 
pathogenesis, we also analyzed their expression levels in Eµ-Myc transgenic mouse model 
that resembles an aggressive Burkitt pathogenesis at 6/8 months of life. By analyzing CD-
19+ B cells from the spleen of Eµ-Myc transgenic mice and litter mate WT we found that miR-
221 and miR-222 levels show a severe down-regulation. This common pattern between 
human and mice suggests that miR-221 and miR-222 are involved in BL pathogenesis. In 
agree with these results, mir-221 and miR-222 ectopic re-expression in BL cell line (Bjab) 
reveals interesting new cellular pathways that could be regulated by this class of miRNAs in 
lymphoma cells. Also, comparing this gene expression profile with a gene expression profile 
obtained from the mouse model we were able to find a common target that could be 
considered to play a role in the BL pathogenesis. Thus, further studies, such as western blot 
analysis in BL cell lines, qRT-PCR and western blot analyses in mouse samples, need to be 
assessed to validate this protein as a target of the cluster 221/222.  
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Our preliminary data on the in vivo mouse model obtained by mating miR-221/222 KO with 
EµMyc tg mice support our results previously reported: the knockout mouse for miR-
221/222 doesn’t show any particular phenotype but when we cross the miR-221/222 KO 
with the well-known in vivo model for BL we observe an anticipation of the disease 
appearance of at least 60 days compared to the wt 221/222-EµMyc tg, indicating that the 
translocation of Myc needs also the dysregulation of the miR-221 and miR-222 to develop 
the malignancy. Unfortunately the number of mice is not enough for statistical analysis so 
we are increasing the litters and furthers studies need to be carry out to establish this KO/tg 
mouse model as a good in vivo BL model. 
 
Our findings indicate that miR-221/222 can be critical mediators for BL pathogenesis and 
together with other important genetics alteration such as translocation of Myc can lead to 
the aggressive phenotype that this B cell malignancy usually shows. These results highlight 
the potential role of this cluster of microRNAs to be a good tool of diagnosis and prognosis 
for BL. 
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